DK1360202T3 - Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser - Google Patents

Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser

Info

Publication number: DK1360202T3
Authority: DK; Denmark
Prior art keywords: disorders; glp; glucagon; peptide; prolonged
Prior art date: 2001-02-16

Application number

DK02700079T

Other languages

English (en)

Inventor

Karen Thibaudeau

Dominique P Bridon

Nissab Boudjellab

Roger Leger

Martin Robitaille

Julie Carette

Original Assignee

Conjuchem Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-16

Filing date

2002-02-15

Publication date

2008-09-22

2002-02-15 Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc

2008-09-22 Application granted granted Critical

2008-09-22 Publication of DK1360202T3 publication Critical patent/DK1360202T3/da

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title 2
102100040918 Pro-glucagon Human genes 0.000 title 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title 2
208000018522 Gastrointestinal disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK02700079T 2001-02-16 2002-02-15 Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser DK1360202T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26927601P	2001-02-16	2001-02-16
PCT/CA2002/000175 WO2002066511A2 (en)	2001-02-16	2002-02-15	Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders

Publications (1)

Publication Number	Publication Date
DK1360202T3 true DK1360202T3 (da)	2008-09-22

Family

ID=23026568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02700079T DK1360202T3 (da)	2001-02-16	2002-02-15	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser

Country Status (14)

Country	Link
US (3)	US7112567B2 (da)
EP (2)	EP1980572A1 (da)
JP (4)	JP4280070B2 (da)
AP (1)	AP1886A (da)
AT (1)	ATE396202T1 (da)
AU (1)	AU2002233089B2 (da)
CA (1)	CA2436399A1 (da)
CY (1)	CY1108274T1 (da)
DE (1)	DE60226702D1 (da)
DK (1)	DK1360202T3 (da)
EA (1)	EA006160B1 (da)
ES (1)	ES2307718T3 (da)
PT (1)	PT1360202E (da)
WO (1)	WO2002066511A2 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) *	2002-07-31	2004-12-30	Peter Bakis	Long lasting natriuretic peptide derivatives
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) *	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
DK1360202T3 (da)	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ES2298378T3 (es) *	2001-06-28	2008-05-16	Novo Nordisk A/S	Formulacion estable de glp-1 modificado.
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
EP1608680A2 (en) *	2003-03-24	2005-12-28	Novo Nordisk A/S	Glp-2 derivatives
EP1633391B1 (en) *	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) *	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
KR101243648B1 (ko) *	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
ES2347902T3 (es) *	2004-04-23	2010-11-22	Conjuchem Biotechnologies Inc. Canadian Corporation 4528590	Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
JP4965446B2 (ja) *	2004-08-31	2012-07-04	ノヴォノルディスクアー／エス	ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
DK1809318T3 (da)	2004-11-01	2013-09-08	Nps Pharma Inc	Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
RU2413530C9 (ru)	2004-11-12	2021-05-18	Ново Нордиск А/С	Стабильные препараты инсулинотропных пептидов
US8088508B2 (en)	2005-01-31	2012-01-03	Panasonic Corporation	Thermal battery
DE602006020123D1 (de) *	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2- (glp-2-) analoga
AU2006321743A1 (en) *	2005-10-24	2007-06-14	Centocor, Inc.	GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US7812121B2 (en) *	2006-08-31	2010-10-12	Baker Audrey E	GLP-2 mimetibodies, polypeptides, compositions, methods and uses
AU2007319066B2 (en) *	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
US20090099074A1 (en) *	2007-01-10	2009-04-16	Conjuchem Biotechnologies Inc.	Modulating food intake
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
WO2009033714A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
CN105727261A (zh) *	2008-06-27	2016-07-06	杜克大学	包含弹性蛋白样肽的治疗剂
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en)	2009-10-23	2011-04-27	Ferring B.V.	Peptidic GLP-2 agonists
JP5908478B2 (ja) *	2010-08-30	2016-04-26	エヌピーエスファーマシューティカルズインコーポレイテッドＮｐｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
KR101895047B1 (ko)	2011-12-30	2018-09-06	한미사이언스 주식회사	면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru)	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
MX349035B (es)	2012-05-17	2017-07-07	Extend Biosciences Inc	Portadores para el suministro mejorado de farmaco.
US9789197B2 (en)	2014-10-22	2017-10-17	Extend Biosciences, Inc.	RNAi vitamin D conjugates
WO2016065052A1 (en)	2014-10-22	2016-04-28	Extend Biosciences, Inc.	Insulin vitamin d conjugates
US9585934B2 (en)	2014-10-22	2017-03-07	Extend Biosciences, Inc.	Therapeutic vitamin D conjugates
CN108473547A (zh) *	2015-10-28	2018-08-31	塔夫茨大学	具有改良的蛋白质分解安定性的新颖多肽，以及制备与使用该新颖多肽的方法
EP4303228B1 (en)	2016-07-11	2026-05-27	OPKO Biologics Ltd.	Long-acting coagulation factor vii and methods of producing same
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
WO2018157131A1 (en)	2017-02-27	2018-08-30	Urigen N.A.	Treatment of lower urinary tract epithelium with glucagon like peptide 2
IL271245B2 (en)	2017-06-16	2023-10-01	Zealand Pharma As	Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
BR112020002804A2 (pt)	2017-08-24	2020-07-28	Novo Nordisk A/S	composição farmacêutica líquida, e, kit
AR113258A1 (es) *	2017-09-28	2020-03-11	Hanmi Pharm Ind Co Ltd	Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
CN108395469A (zh) *	2018-02-01	2018-08-14	滨海吉尔多肽有限公司	一种假脯氨酸二肽的合成方法
WO2020020904A1 (en)	2018-07-23	2020-01-30	Zealand Pharma A/S	Therapeutic uses of glp-2 agonists
EP3628682A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20200254065A1 (en) *	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
JP2022552655A (ja)	2019-10-07	2022-12-19	キャリーオペ，インク．	Ｇｐｒ１１９アゴニスト
IL294521A (en)	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
MX2022010548A (es)	2020-02-28	2022-09-23	Kallyope Inc	Agonistas de gpr40.
EP4120958B1 (en)	2020-03-18	2026-04-29	Takeda Pharmaceutical Company Limited	Implantable cell chamber device and uses thereof
MX2022014505A (es)	2020-05-19	2022-12-13	Kallyope Inc	Activadores de la ampk.
CA3183575A1 (en)	2020-06-26	2021-12-30	Iyassu Sebhat	Ampk activators
US12233115B2 (en)	2022-09-30	2025-02-25	Extend Biosciences, Inc.	Long-acting parathyroid hormone

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1160380A (en) *	1966-12-22	1969-08-06	Ford Motor Co	Vehicle Engine Arrangement.
US3719667A (en)	1970-08-24	1973-03-06	Lilly Co Eli	Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en)	1971-05-28	1974-10-08	Lilly Co Eli	Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE3241416A1 (de) *	1982-01-19	1983-07-28	Josef Gartner & Co, 8883 Gundelfingen	Isolierverglasung
US4462941A (en) *	1982-06-10	1984-07-31	The Regents Of The University Of California	Dynorphin amide analogs
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
US5612034A (en) *	1990-10-03	1997-03-18	Redcell, Inc.	Super-globuling for in vivo extended lifetimes
US5843440A (en) *	1990-10-03	1998-12-01	Redcell Canada, Inc.	Cellular and serum protein anchors for modulating pharmacokinetics
DK0578728T3 (da) *	1991-04-05	1999-04-12	Genentech Inc	Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
DE4122210C2 (de)	1991-07-04	1999-04-01	Deutsches Krebsforsch	Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
CZ281630B6 (cs)	1992-06-12	1996-11-13	Des-Tyr Dynorphin Partnership	Analogy des-tyr dynorfinu
EP0602290B1 (en)	1992-12-04	1999-08-25	ConjuChem, Inc.	Antibody-conjugated Hepatitis B surface antigen and use thereof
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5580853A (en) *	1994-03-22	1996-12-03	New England Deaconess Hospital	Modified polypeptides with increased biological activity
US5496007A (en) *	1994-05-13	1996-03-05	Reece; Cecil L.	Device for holding out-sized documents
AU7637394A (en)	1994-08-26	1996-03-22	Avram Goldstein	Analgesic method with dynorphin analogues truncated at the n-terminus
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) *	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5654276A (en) *	1995-06-07	1997-08-05	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
AU713616B2 (en)	1996-01-12	1999-12-09	Conjuchem, Inc.	Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en)	1996-02-07	2001-08-21	Conjuchem, Inc.	Affinity labeling libraries and applications thereof
AU723694B2 (en)	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
US5840733A (en)	1996-07-01	1998-11-24	Redcell, Canada, Inc.	Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
DE69740096D1 (de)	1996-08-08	2011-02-17	Amylin Pharmaceuticals Inc	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
EP0929576A1 (en) *	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivatives
WO1998011437A1 (en)	1996-09-16	1998-03-19	Conjuchem, Inc.	Affinity labeling libraries with tagged leaving groups
ES2181054T3 (es) *	1996-12-06	2003-02-16	Amgen Inc	Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
US6723530B1 (en)	1997-02-05	2004-04-20	Amylin Pharmaceuticals, Inc.	Polynucleotides encoding proexendin, and methods and uses thereof
US6051557A (en) *	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
ES2293688T5 (es)	1997-08-08	2011-05-04	Amylin Pharmaceuticals, Inc.	Nuevos compuestos análogos de la exendina.
DE69812727D1 (de)	1997-11-07	2003-04-30	Conjuchem Inc	Opioid-konjugate mit endogenen Trägerproteinen
ATE406577T1 (de)	1997-11-07	2008-09-15	Conjuchem Biotechnologies Inc	Methoden zum screening von affinitätsmarker- bibliotheken
US6437092B1 (en)	1998-11-06	2002-08-20	Conjuchem, Inc.	Conjugates of opioids and endogenous carriers
CA2309955A1 (en)	1997-11-12	1999-05-20	Alza Corporation	Method for decreasing self-association of polypeptides
CA2309356C (en)	1997-11-14	2010-09-21	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU2712899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU3247799A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en)	1998-03-17	2000-08-22	Conjuchem, Inc.	Extended lifetimes in vivo renin inhibitors
IL133053A0 (en)	1998-03-23	2001-03-19	Conjuchem Inc	Local delivery of long lasting therapeutic agents
US20030170250A1 (en)	1998-03-23	2003-09-11	Ezrin Alan M.	Local delivery of long lasting therapeutic agents
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en)	1999-09-10	2005-05-03	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1179012B2 (en)	1999-05-17	2009-07-15	ConjuChem Biotechnologies Inc.	Long lasting fusion peptide inhibitors of viral infection
EP1171582A2 (en)	1999-05-17	2002-01-16	Conjuchem, Inc.	Long lasting anti-angiogenic peptides
US20040266673A1 (en)	2002-07-31	2004-12-30	Peter Bakis	Long lasting natriuretic peptide derivatives
AU765753B2 (en) *	1999-05-17	2003-09-25	Conjuchem Biotechnologies Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt)	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US7144854B1 (en)	1999-09-10	2006-12-05	Conjuchem, Inc.	Long lasting anti-angiogenic peptides
US6849714B1 (en)	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
DE19926154A1 (de)	1999-06-09	2000-12-14	Ktb Tumorforschungs Gmbh	Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de)	1999-06-10	2000-12-14	Ktb Tumorforschungs Gmbh	Träger-Pharmaka-Konjugate
US6706892B1 (en)	1999-09-07	2004-03-16	Conjuchem, Inc.	Pulmonary delivery for bioconjugation
EP1235618A2 (en)	1999-09-07	2002-09-04	Conjuchem, Inc.	Bioconjugation in vivo to pulmonary or blood components
US7090851B1 (en)	1999-09-10	2006-08-15	Conjuchem Inc.	Long lasting fusion peptide inhibitors of viral infection
DE10012120A1 (de)	2000-03-13	2001-09-27	Ktb Tumorforschungs Gmbh	Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CA2435563A1 (en)	2001-02-02	2002-08-15	Conjuchem Inc.	Long lasting growth hormone releasing factor derivatives
DK1360202T3 (da)	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ES2242860T3 (es)	2001-05-31	2005-11-16	Conjuchem, Inc.	Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
US6882816B2 (en) *	2002-02-19	2005-04-19	Matsushita Electric Industrial Co., Ltd.	Developing device with developer circulating path
EP1530588A2 (en)	2002-07-31	2005-05-18	Conjuchem, Inc.	Long lasting natriuretic peptide derivatives
SI1648933T1 (sl)	2003-07-25	2010-01-29	Conjuchem Biotechnologies Inc	Dolgo delujoäś inzulinski derivat in metoda zanj
ES2347902T3 (es)	2004-04-23	2010-11-22	Conjuchem Biotechnologies Inc. Canadian Corporation 4528590	Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en)	2005-12-22	2007-06-28	Conjuchem Biotechnologies Inc.	Process for the production of preformed conjugates of albumin and a therapeutic agent

2002
- 2002-02-15 DK DK02700079T patent/DK1360202T3/da active
- 2002-02-15 WO PCT/CA2002/000175 patent/WO2002066511A2/en not_active Ceased
- 2002-02-15 US US10/203,808 patent/US7112567B2/en not_active Expired - Fee Related
- 2002-02-15 DE DE60226702T patent/DE60226702D1/de not_active Expired - Lifetime
- 2002-02-15 AU AU2002233089A patent/AU2002233089B2/en not_active Ceased
- 2002-02-15 EP EP08156596A patent/EP1980572A1/en not_active Withdrawn
- 2002-02-15 PT PT02700079T patent/PT1360202E/pt unknown
- 2002-02-15 AT AT02700079T patent/ATE396202T1/de active
- 2002-02-15 EA EA200300857A patent/EA006160B1/ru not_active IP Right Cessation
- 2002-02-15 ES ES02700079T patent/ES2307718T3/es not_active Expired - Lifetime
- 2002-02-15 CA CA002436399A patent/CA2436399A1/en not_active Abandoned
- 2002-02-15 JP JP2002566224A patent/JP4280070B2/ja not_active Expired - Lifetime
- 2002-02-15 EP EP02700079A patent/EP1360202B1/en not_active Expired - Lifetime
- 2002-11-13 AP AP2005003310A patent/AP1886A/xx active
2005
- 2005-12-23 US US11/318,323 patent/US7737251B2/en not_active Expired - Fee Related
2008
- 2008-03-28 JP JP2008088237A patent/JP2008179652A/ja active Pending
- 2008-08-20 CY CY20081100886T patent/CY1108274T1/el unknown
- 2008-10-10 JP JP2008264644A patent/JP2009035568A/ja not_active Withdrawn
2009
- 2009-07-19 US US12/505,506 patent/US20090312259A1/en not_active Abandoned
2010
- 2010-03-03 JP JP2010046750A patent/JP2010150276A/ja active Pending

Also Published As

Publication number	Publication date
EP1980572A1 (en)	2008-10-15
CY1108274T1 (el)	2014-02-12
EA200300857A1 (ru)	2003-12-25
CA2436399A1 (en)	2002-08-29
EP1360202A2 (en)	2003-11-12
ES2307718T3 (es)	2008-12-01
DE60226702D1 (de)	2008-07-03
EP1360202B1 (en)	2008-05-21
AU2002233089B2 (en)	2005-12-22
JP2004532819A (ja)	2004-10-28
PT1360202E (pt)	2008-09-01
AP2005003310A0 (en)	2005-06-30
AP1886A (en)	2008-09-20
JP4280070B2 (ja)	2009-06-17
WO2002066511A2 (en)	2002-08-29
WO2002066511A3 (en)	2003-03-06
EA006160B1 (ru)	2005-10-27
US7737251B2 (en)	2010-06-15
US7112567B2 (en)	2006-09-26
ATE396202T1 (de)	2008-06-15
US20040248782A1 (en)	2004-12-09
US20090312259A1 (en)	2009-12-17
US20060217304A1 (en)	2006-09-28
JP2008179652A (ja)	2008-08-07
JP2010150276A (ja)	2010-07-08
JP2009035568A (ja)	2009-02-19

Publication	Publication Date	Title
PT1360202E (pt)	2008-09-01	Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
IS2625B (is)	2010-05-15	4(fenýl-píperasinýl-metýl)bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DK1286668T3 (da)	2005-08-15	Farmaceutiske kombinationer indeholdende tegaserod og omeprazol og deres anvendelse til behandling af gastrointestinale sygdomme
IS7189A (is)	2004-03-19	Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
IS7185A (is)	2004-03-16	Glúkagon-líkir-peptíð-1 hermar í mönnum og notkunþeirra við meðhöndlun sykursýki og skylds ástands
NO20040246L (no)	2004-04-01	TACI'er- og BR3-polypeptider og anvendelser derav
EP1372739A4 (en)	2005-10-19	STABILIZED THERAPEUTIC AND IMAGING AGENTS
IS2457B (is)	2008-11-15	Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
NO20033123D0 (no)	2003-07-08	Terapeutisk hinnedannende sammensetning og behandlingsplan derav
EP1406493A4 (en)	2006-06-14	ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
IS6966A (is)	2003-09-24	Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS7863A (is)	2005-05-25	4 (fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum
IS7026A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
EP1462455A4 (en)	2008-12-31	NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS
NO20023448L (no)	2002-09-17	Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
IS7864A (is)	2005-05-25	4(fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum
DK1408949T3 (da)	2008-04-28	Glycinbetain og dets brugområde for opfindelsen
IS7027A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
AU2003278664A1 (en)	2004-06-07	4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
IS7025A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
DK1357910T3 (da)	2005-08-08	Fremgangsmåde til forebyggelse og behandling af smerter i de indre organer og mavetarmlidelser
IS7028A (is)	2003-11-12	4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7029A (is)	2003-11-12	4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum
IS7024A (is)	2003-11-11	4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum